European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure: document with tracked changes

European Medicines Agency pre-authorisation procedural advice for users of the centralised procedure

Opinion/decision on a Paediatric investigation plan (PIP): Xofluza, Baloxavir marboxil, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infectious diseases, PIP number: P/0359/2023

EMEA-003436-PIP01-23

EMEA-003438-PIP01-23

EMEA-003444-PIP01-23

EMEA-003447-PIP01-23

Data protection and privacy

European Medicines Agency's privacy statement for selection and recruitment

EMA Management Board: highlights of October 2024 meeting